Biocompatible Dendritic Polypeptides for Delivery of Multiple Small-Molecule Therapeutics and siRNAs

Keyphrases

• Application Delivery 16%
• Attractive Alternatives 16%
• Biocompatibility 100%
• Biodegradability 33%
• Brain Cancer Cells 16%
• Co-delivery 16%
• Conjugation 16%
• Conventional Drugs 16%
• Cytotoxicity 16%
• Dendrimer 50%
• Development Status 16%
• Doxorubicin 16%
• Drug Delivery Platform 16%
• Drug Dosage 16%
• Drug Resistance 16%
• High Biocompatibility 16%
• High Molecular Weight 16%
• Histone Deacetylase Inhibitor (HDACi) 16%
• Immune Response 16%
• Immunogenicity 16%
• Inherent Toxicity 16%
• Intellectual Development 16%
• Intellectual Property 16%
• Low Immunogenicity 16%
• Low Molecular Weight 16%
• Low Toxicity 16%
• Market Application 16%
• Monodispersity 16%
• Multiple Drugs 16%
• Nano-drug Delivery System 16%
• Nucleic Acids 16%
• Polypeptide 100%
• Potential Reduction 16%
• Property Development 16%
• Property Status 16%
• Rutgers 16%
• Small Interfering RNA (siRNA) 100%
• Small Molecule Acid 16%
• Small Molecule Therapeutics 100%
• Surface Functionality 16%
• Synergistic Effect 16%
• Synergistic Therapeutic Effect 16%
• Synthetic Process 16%
• Topoisomerase Inhibitors 16%
• Tumor Cell Death 16%
• Unique Characteristics 16%
• US Patents 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Biocompatibility 33%
• Brain Cancer 16%
• Cytotoxicity 16%
• Dendrimer 50%
• Disease 16%
• DNA Topoisomerase Inhibitor 16%
• Doxorubicin 16%
• Drug Delivery System 16%
• Drug Resistance 16%
• Histone Deacetylase Inhibitor 16%
• Immunogenicity 33%
• Malignant Neoplasm 16%
• Micelle 16%
• Nanoparticle 16%
• Neoplasm 16%
• Nucleic Acid 16%
• Polypeptide 100%
• Side Effect 16%
• Small Interfering RNA 100%
• Therapeutic Effect 16%
• Vorinostat 16%